Development of Postpartum Care Model for Pregnant Women with Methamphetamine Use in Kalasin Province
DOI:
https://doi.org/10.64960/srimedj.v40i5.267588Keywords:
pregnant women, methamphetamine, postpartum care, methamphetamine relapse prevention, family therapyAbstract
Background and Objective: Methamphetamine use during pregnancy severely impacts both mothers and infants. Effective postpartum care is crucial for methamphetamine relapse prevention and promoting maternal and infant health. This study aimed to develop and evaluate the effectiveness of a postpartum care model for pregnant women with methamphetamine use in Kalasin Province.
Methods: This research and development (R & D) followed Kemmis and McTaggart's framework, comprising planning, action, observation, and reflection phases. The sample consisted of 88 postpartum women with a history of methamphetamine use in Kalasin Province. The care model included hospital assessment on the second day postpartum, home visits within one week after discharge, postpartum examination at 4-6 weeks with group therapy, home visits at 8-12 weeks, and hospital assessment at 24 weeks. Data collection instruments included a personal information interview form, family readiness assessment (FRA), and relapse risk assessment form. Data were analyzed using frequency, percentage, mean, standard deviation, Kolmogorov-Smirnov, and ANOVA.
Results: Comparing before and after intervention, significant improvements were observed in home environment, family bonding, acceptance and forgiveness, and social networking (p<0.01). The risk of relapse significantly decreased (p=0.02), with high-risk cases reducing from 68.20% to 25.00%. Family readiness for patient care showed the greatest improvement in problem-solving capacity (from 21.20% to 87.90%), role recognition and performance (from 42.40% to 97.00%), and knowledge of patient care (from 27.30% to 54.50%).
Conclusion: The developed postpartum care model for pregnant women with methamphetamine use effectively reduced relapse risk and enhanced family readiness for patient care, with significant improvements in environmental conditions, family relationships, and social support. This model can be applied to the care of postpartum women with a history of methamphetamine use in other areas to improve the quality of life for both mothers and infants.
References
United Nations Office on Drugs and Crime. World Drug Report 2023. Vienna: United Nations; 2023.
Degenhardt L, Baxter AJ, Lee YY, Hall W, Sara GE, Johns N, et al. The global burden of disease attributable to alcohol and drug use in 195 countries and territories, 2016-2019: a systematic analysis for the global burden of disease study 2019. Lancet Psychiatry 2022;9(4):301-12 doi:10.1016/S0140-6736(18)31310-2.
Substance Abuse and Mental Health Services Administration. Key substance use and mental health indicators in the United States: results from the 2022 national survey on drug use and health. Rockville, MD: SAMHSA; 2023.
Grzeskowiak LE, Smithers LG, Grieger JA, Bianco-Miotto T, Leemaqz SY, Clifton VL, et al. Detection of prenatal substance exposure using clinical and self-reported measures: a longitudinal study. Birth Defects Res 2022;114(4):139-51. doi:10.1016/j.earlhumdev.2020.105119 .
European Monitoring Centre for Drugs and Drug Addiction. Pregnancy, childcare and the family: key issues for Europe's response to drugs. Luxembourg: Publications Office of the European Union; 2021. doi:10.2810/72819.
Thaithumyanon P, Limpongsanurak S, Praisuwanna P, Punnahitanon S. Perinatal effects of amphetamine and heroin use during pregnancy: a retrospective cohort study. Drug Alcohol Depend 2021;116(1-2):126-30.
Wright TE, Schuetter R, Fombonne E, Stephenson J, Haning WF. Implementation and evaluation of a harm-reduction model for clinical care of substance using pregnant women. Harm Reduct J 2022;19(1):24. doi:10.1186/1477-7517-9-5.
Terplan M, Minkoff H. Neonatal abstinence syndrome and ethical approaches to the identification of pregnant women who use drugs. Obstet Gynecol 2023;140(2):368-74 doi:10.1097/AOG.0000000000001781.
McQueen K, Murphy-Oikonen J. Neonatal abstinence syndrome: a comprehensive review of assessment and management. Adv Neonatal Care. 2022;22(3):216-28 doi:10.1056/NEJMra1600879.
Narkowicz S, Krawczyk-Grycz M, Kot-Wasik A, Czarnowski W, Namieśnik J. Development and validation of a GC-MS method for the simultaneous determination of illicit psychoactive drugs in human urine for the monitoring of pregnant patients. Obstet Gynecol Int 2022;2022:9472658 doi:10.1007/s11419-019-00485-y.
Yamane T. Statistics: an introductory statistic. 2nd ed. New York: Harper & Row; 1973.
Aonopas S, Youhunnao. Tools for Social Work Practice. Bangkok: Faculty of Social Sciences and Social Welfare, Huachiew Chalermprakiet University and Thammasat Hospital; 2021.
Thumwong N. Development of Behavior change curriculum to reduce harm on Amphetamine-Type stimulants use in Thailand [dissertation]. Khon Kaen: Khon Kaen University; 2019.
Wouldes TA, LaGasse LL, Derauf C, Newman E, Shah R, Smith LM, et al. Co-morbidity of substance use disorder and psychopathology in women who use methamphetamine during pregnancy in the US and New Zealand. Drug Alcohol Depend. 2013;127(1-3):101-7. doi:10.1016/j.drugalcdep.2012.06.016.
Wright TE, Schuetter R, Fombonne E, Stephenson J, Haning WF. Implementation and evaluation of a harm-reduction model for clinical care of substance using pregnant women. Harm Reduct J 2018;15(1):52. doi:10.1186/1477-7517-9-5.
Terplan M, Ramanadhan S, Locke A, Longinaker N, Lui S. Psychosocial interventions for pregnant women in outpatient illicit drug treatment programs compared to other interventions. Cochrane Database Syst Rev 2015;(4):CD006037. doi:10.1002/14651858.CD006037.pub3.
Jones HE, Kaltenbach K, Heil SH, Stine SM, Coyle MG, Arria AM, et al. Neonatal abstinence syndrome after methadone or buprenorphine exposure. N Engl J Med 2010;363(24):2320-31. doi:10.1056/NEJMoa1005359.
McQueen K, Murphy-Oikonen J. Neonatal abstinence syndrome: a comprehensive review of assessment and management. Adv Neonatal Care 2016;16(5):379-86. doi:10.1056/NEJMra1600879.
Ordean A, Kahan M. Comprehensive treatment program for pregnant substance users in a family medicine clinic. Can Fam Physician 2011;57(11):e430-5.
Grzeskowiak LE, Morrison JL. Long-term effects of prenatal exposure to drugs of abuse. J Pediatr Neonatal Individ Med 2016;5(2):e050244. doi:10.1016/s0889-8545(05)70364-8.
Degenhardt L, Grebely J, Stone J, Hickman M, Vickerman P, Marshall BDL, et al. Global patterns of opioid use and dependence: harms to populations, interventions, and future action. Lancet 2019;394(10208):1560-79. doi:10.1016/S0140-6736(19)32229-9.
United Nations Office on Drugs and Crime. International standards for the treatment of drug use disorders. Vienna: United Nations; 2020.
Substance Abuse and Mental Health Services Administration. Clinical guidance for treating pregnant and parenting women with opioid use disorder and their infants. Rockville, MD: SAMHSA; 2018.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Srinagarind Medical Journal
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
